SMS alerts can make the difference between a profitable trade and a missed opportunity.
 Text “MOMO” to 555888 to receive our instant, reliable and free SMS alerts.

Good morning all,

ETST is trading steady this morning on good opening volume. We didn't get the breakout follow through from yesterday's strong close largely because of a big seller at $0.94, but we're still hopeful and keeping a very close eye.

Independent website http://squeezereport.com has put out a report on ETST detailing the estimate short position in this ticker. 

Squeeze Reports’ Short Analysis Tool from the proprietary predictive stock-trading algorithm software estimates ETSTs’ short totals as of December 19^th, 2017;

Estimated Shares Shorted: 923,372
Estimated Shares Covered: 668,587
Estimated Shares Still Short: 254,785

There appears to be major short interest in ETST. If we see more upside momentum, a short squeeze could easily be triggered.

You want to be positioned in the event of a short squeeze because a move to the upside could be fast and profitable.

Keep your attention fully on ETST today and look for opportunities here.

All the best.

SmallCapMomo.com


-------------------------------------------------------------------------------


Traders and Investors,

You will remember we alerted you to ETST last week. Well, I sent you an email about it yesterday afternoon as it was attempting to breakout and it ended up closing right near the high of the day, and its highest close in the past 5 months.

Hopefully we see a gap up and the momentum continue this morning.

ETST is breaking out technically right now, and you should be paying attention.

As you can see, there was a strong breakout just a few days ago, followed by a small pullback and consolidation. Now comes the major phase of the breakout, which is often the biggest and most explosive.

And there are some well defined targets. $1 is the first and most obvious, and then its six month high of around $1.20 is the second target if things get frothy.

If this breakout builds on the momentum its had in the past week or so, we could see a lot more upside.

ETST has announced some nice news catalysts in recent days.

Last week they announced they had signed a distribution agreement with Mr. Checkout, beginning in 2018, and coinciding with the company’s new CBD product revamp.

And just a couple days ago ETST announced they have engaged counsel to prepare an offering for shares of its common stock to be qualified by the SEC under Tier II of Regulation A+. 

ETST intends to raise capital in order to finalize and commercialize its projects through Earth Science Pharmaceutical and Cannabis Therapeutics. As previously announced, the Company’s MSN-2 medical device is prepared for third-party evaluation and then to be manufactured and commercialized.

The Company has projected costs for its MSN-2 medical device of approximately $500,000 for all of the aforementioned tasks to be completed. It is projected to generate over $2 million in revenue during the first year of production alone, based on sales through its current distribution channels.



ETST is a biotech that could be on every investors radar soon.

ETST has a small float and a breakout chart that is screaming to be traded.

Just check out this hugely bullish rating BarChart.com gives ETST.

As you can see, there was a strong breakout just a few days ago, followed by a small pullback and consolidation. Now comes the major phase of the breakout, which is often the biggest and most explosive.

And there are some well defined targets. $1 is the first and most obvious, and then its six month high of around $1.20 is the second target if things get frothy.

If this breakout builds on the momentum its had in the past week or so, we could see a lot more upside.

ETST has had several big developments in recent weeks, we encourage you to start looking through the company's news right away. 

ETST is a unique innovative biotechnology company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices to improving the quality of life for Consumers Worldwide.

The legal marijuana sector has been compared to the dot.com boom of the 90's. It is growing incredibly fast and it's practically everyday that another state is considering to make the drug legal recreationally or medicinally.

One of the most promising aspects is the hemp sector due to the fact that it's legal in all 50 states already. 

ETST has high grade CBD (Cannabidiol) Rich Hemp oil that is classified as “food based” by the FDA and is therefore perfectly permissible in all 50 US states and roughly 40 countries.

With no psychoactive ingredient, CBD is a ready-for-market hemp-based nutraceutical. 

You can check out all of the company's website at https://earthsciencetech.com/

CBD has the potential to help a range of conditions and disorders. The fact that there is no THC makes it safe for adults, children, and even pets.

It has anti-inflammatory properties, can be used to reduce anxiety, help acne, treat seizures, pain, assist in treating cancer.. the list goes on and on. 

ETST has something pretty big going on which could be what quickly gets it recognized.

The company is a part of MSN-2 human clinical trials with Clinique Santa Amite,  a clinic specialized in the detection and treatment of sexually transmitted infections.

It was just earlier last month that the company pre-launched the trials. 

The previously announced pre-launch clinical study, has been initiated. 

Patient enrollment has already begun, and the reactions to the study and the product have been very positive thus far. The general approval and acceptance of the product’s self-sampling basis has led to the nurses having no difficulty enrolling participants.

ETST's MSN-2 medical device has the potential to decrease the spread of HIV by reducing the prevalence of chlamydia in young women.

It is fact that when a woman is infected with chlamydia, her risk of contracting HIV is five times the risk of a woman who does not have chlamydia. In addition, chlamydia is the main cause of female infertility in industrialized countries. 

An undiagnosed, asymptomatic chlamydia infection spreads through the reproductive organs and causes irreversible damage to the woman, requiring specialized care including hospitalization and the administration of intravenous antibiotics, and may have serious effects on any unborn child she is carrying.

ETST CEO and Chief Scientific Officer Dr. Michel Aubé, held a preceptorship with Dr. Jean Robert, a physician at Clinique Santé Amitié recently. 

Dr. Aubé spent a full afternoon with Dr. Robert and his patients, sitting in on their private consultations. The goal of this rapprochement is to demonstrate the reality of AIDS and HIV to health workers and other people and institutions interested in helping fight this deadly pandemic.

“This exercise reinforces our desire to prevent the transmission of avoidable infections and to help people living with incurable illnesses,” said Dr. Aubé. 

Nickolas S. Tabraue, ETST's President, Director, & COO ends with, “We currently have all our partners - Canadian, American, and world-wide looking forward to the launch of the new MSN-2 device for women.

More than 70 million people have been infected with the HIV virus and about 35 million people have died of HIV.

This is an epidemic that receives a lot of attention and ETST's revolutionary product could quickly capture the attention of Wall Street.

So, with a breakout chart, small float and plenty of news catalysts, ETST could be an awesome trader today and in coming days.

So your due diligence and make sure to read through the recent press releases.

All the best.

SmallCapMomo.com

Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity.